NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E, Serna-Blasco R, Ivanchuk V, García-Campelo R, Dómine Gómez M, Sánchez JM, Massutí B, Reguart N, Camps C, Sanz-Moreno S, Calabuig-Fariñas S, Jantus-Lewintre E, Arnal M, Fernández-Orth D, Calvo V, González-Rumayor V, Provencio M, Romero A.
Sánchez-Herrero E, et al. Among authors: fernandez orth d.
Mol Oncol. 2021 Sep;15(9):2363-2376. doi: 10.1002/1878-0261.13033. Epub 2021 Jun 18.
Mol Oncol. 2021.
PMID: 34058070
Free PMC article.